Editor's Note: Louis Navellier has spent 40+ years identifying stocks before major tech waves — his system helped him flag. Nvidia before its 82,000% run. Today, he's revealing the three stocks at the center of the biggest AI buildout in history. Click here for the full story or read more below.
Dear Reader,
Goldman Sachs just predicted 300 million jobs will disappear.
Not in 10 years. Not in 5.
This is starting NOW.
30,000 layoffs at UPS. 16,000 at Amazon. Factories are going "lights out" with zero human workers.
And now Elon Musk's "Project Apex" is set to accelerate this labor crisis.
A Nobel Prize-winning scientist says what Elon is building "could have an even greater impact on society than the internet."
Nvidia's CEO calls it "superhuman."
And competitors are so panicked, they're flying spy planes over the facility to figure out how it works.
I've spent 40+ years analyzing technological shifts like this. My proprietary system has helped me identify winning stocks before every major tech wave.
I'm telling you because on the OTHER side of this disruption is a historic investment opportunity.
The last time a technology shift this big happened, early investors in the right supply-chain stocks had the chance to see extraordinary gains. Lithium Americas: 1,452%. NIO: 1,755%. Blink Charging: 3,648%. All in under two years.
I've pinpointed one tiny company at the center of Elon's AI revolution — 49 times smaller than Tesla — that's become the "secret weapon" of Microsoft, Meta, Amazon, and Google. I'll also share two more stocks positioned for this wave — but I believe this one is the must-own.
Biotech Is Booming Again: Here’s Why Investors Are Paying Attention
Posted On Jul 07, 2026 by Ian Cooper
The biotech sector is booming thanks to a strong resurgence of mergers and acquisitions.
Table of Contents
Biotech stocks are back in the spotlight as pharmaceutical mergers, breakthrough drug discoveries, and advances in artificial intelligence fuel renewed optimism across the biotechnology sector. In fact, investors are once again looking at biotech companies as potential growth opportunities, driven by billions of dollars in acquisition activity, promising clinical trial results, and a wave of innovation in gene editing, cancer therapies, and precision medicine. For investors seeking exposure to this fast-growing industry, biotech ETFs have also emerged as a popular way to diversify.
A new AI crisis is spiking power bills across America. It's part of a $33 trillion problem for the stock market... which experts warn could cause a crash 62 times worse than The Great Depression if it isn't fixed fast. See how a new venture backed by Elon Musk and Sam Altman could stop this "AI Tax," save the economy, and send a small group of stocks soaring in the process.
At the moment, larger pharmaceutical companies are buying smaller biotech firms to strengthen their pipelines. Vertex, for example, is acquiring Crinetics Pharmaceuticals in a massive $10 billion deal. The buyout provides Vertex with Palsonify, an FDA-approved drug for the rare endocrine disorder acromegaly, along with other promising pipeline assets.
Bio-Techne Corp for $11.3 billion in cash. Novartis agreed to pay $1.1 billion upfront (up to $1.5 billion total) to buy clinical-stage antibody-drug conjugate (ADC) developer Myricx Bio.
That’s happening because many of the world’s largest drug companies are facing a problem: several of their best-selling medicines will soon lose patent protection. Once that happens, cheaper generic versions can enter the market, reducing profits.
To replace that lost revenue, many pharmaceutical companies are buying biotech firms with promising new drugs instead of spending years developing treatments on their own.
Innovation Is Moving Fast
Biotech has always been driven by innovation, and that hasn’t changed.
Researchers are making progress in areas such as cancer treatments, gene editing, rare diseases, and precision medicine. Artificial intelligence is also helping scientists discover new drug candidates more quickly and efficiently. These advances are giving investors more confidence that the next generation of breakthrough medicines is already being developed.
Several biotech companies have also reported encouraging clinical trial results and received important regulatory approvals this year, helping improve sentiment across the sector.
For people who want exposure to the industry without betting on a single company, biotech exchange-traded funds (ETFs) offer a simple way to invest across dozens of businesses.
With an expense ratio of 0.44%, the iShares Biotechnology ETF (IBB) offers investors a cost-effective way to gain broad exposure to the biotechnology sector. The fund tracks a diversified portfolio of biotechnology and pharmaceutical companies, including both established industry leaders and emerging innovators developing cutting-edge therapies. By investing in a single ETF, investors can reduce the company-specific risk associated with individual biotech stocks while participating in the long-term growth potential driven by advances in drug development, precision medicine, and genetic research.
With an expense ratio of 0.35%, the SPDR S&P Biotech ETF (XBI) provides investors with an affordable way to gain exposure to the biotechnology industry. Unlike market-cap-weighted biotechnology funds, XBI uses an equal-weighted approach, giving smaller and mid-sized biotechnology companies a greater representation alongside larger firms.
This structure offers investors broader exposure to emerging biotech companies that may have significant growth potential driven by innovative drug development, clinical trial successes, and advancements in biotechnology research.
With an expense ratio of 0.95%, the ProShares Ultra Nasdaq Biotechnology ETF (BIB) is designed for investors seeking leveraged exposure to the biotechnology sector. The fund aims to deliver twice (2x) the daily performance of the Nasdaq Biotechnology Index, making it a tactical investment vehicle rather than a traditional long-term holding.
Why Biotech Could Be One of the Market’s Biggest Growth Opportunities
The biotechnology sector appears to be entering a new growth phase, fueled by increased merger and acquisition activity, breakthrough medical innovations, and the growing use of artificial intelligence in drug discovery. As large pharmaceutical companies race to replenish their product pipelines, many smaller biotech firms are becoming attractive acquisition targets, creating new opportunities for investors.
